In 2008, the Korean Breast Cancer Study Group launched the Addition of Ovarian Suppression to Tamoxifen in Young Women
Ovarian suppression therapy is a treatment that may be used for
01 for tamoxifen alone vs With the only exception of patients with low-risk clinical-pathological features
In contrast, AIs inhibit peripheral conversion of androgens to estrogen and
Adding Ovarian Suppression to Tamoxifen for Premenopausal Women
There are several ways to remove or shut down the ovaries to treat breast cancer: Oophorectomy: Surgery to remove the ovaries
This report is restricted to 7030 (97·2%) women with ER-positive tumours
In my experience, the combination of an AI plus ovarian suppression was a little more toxic than tamoxifen plus ovarian suppression
Early adjuvant trials demonstrated that ovarian suppression as the sole adjuvant treatment reduced recurrence and improved survival in women younger than 50 years of age with early-stage breast cancer
Ovarian suppression with tamoxifen or an AI is often recommended for women with a breast cancer that may place them at a higher than average risk of recurrence (including those who are 35 years or younger or who have received chemotherapy)
PMC free article
PURPOSE To determine the updated long-term outcomes of the Addition of Ovarian Suppression to Tamoxifen in Young Women With Hormone-Sensitive Breast Cancer Who Remain Premenopausal or Regain Vaginal Bleeding After Chemotherapy (ASTRRA) trial
the hormonal therapy options include ovarian ablation or suppression, with tamoxifen or an aromatase inhibitor, for up to 10 years
In the same vein, a handful of patients stayed on OS + AI therapy despite not achieving ovarian suppression immediately, whereas others changed to tamoxifen
It may also be recommended as an additional treatment for people taking tamoxifen or for premenopausal women taking an aromatase inhibitor instead of tamoxifen
The evidence was stronger for very young women (<35 years of age) who had a higher risk of recurrence
Background: Suppression of ovarian estrogen production reduces the recurrence of hormone-receptor-positive early breast cancer in premenopausal women, but its value when added to tamoxifen is uncertain
3% in the